Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
1. A compound represented by the following formula:
L 2 ′-A-NH—CR 1 R 2 —S-L 1 -D (II)
or a pharmaceutically acceptable salt thereof, wherein:
L 2 ′ is represented by the following structural formula:
wherein:
R x and R y are both H;
1 and 11 are each an integer from 1 to 10; and
k1 is an integer from 1 to 12;
A is an amino acid or a peptide comprising 2 to 20 amino acids;
R 1 and R 2 are each independently H or a C 1-3 alkyl;
L 1 -L 1 ′—C(═O)—; and L 1 ′ is an alkylene or a cycloalkylene, wherein the —C(═O)—moiety in L 1 is connected to D; and
D is represented by the following formula:
2. The compound of claim 1 , wherein one of R 1 and R 2 is H, and the other one is Me; or R 1 and R 2 are both H.
3. The compound of claim 1 , wherein L 1 is —CR 3 R 4 —(CH 2 ) 1-8 —C(═O)—; R 3 and R 4 are each independently H or Me.
4. The compound of claim 3 , wherein R 3 and R 4 are both Me.
5. The compound of claim 1 , wherein L 1 is —(CH 2 ) 4-6 —C(═O)—.
6. The compound of claim 1 , wherein A is a peptide cleavable by a protease expressed in tumor tissue.
7. The compound of claim 6 wherein A is a peptide having an amino acid that is covalent linked with —NH—CR 1 R 2 —S—L 1 -D selected from the group consisting of Ala, Arg, Asn, Asp, Cit, Cys, selino-Cys, Gln, Glu, Gly, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val, each independently as L or D isomer.
8. The compound of claim 7 , wherein the amino acid connected to —NH—CR 1 R 2 —S—L 1 -D is an L amino acid.
9. The compound of claim 1 , wherein A is selected from the group consisting of Gly-Gly-Gly, Ala-Val, Val-Ala, D-Val-Ala, Val-Cit, D-Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Ala, Phe-N 9 -tosyl-Arg, Phe-N 9 -nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Ala-Ala, D-Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala-D-Ala, Ala-Leu-Ala-Leu (SEQ ID NO: 1), β-Ala-Leu-Ala-Leu (SEQ ID NO: 2), Gly-Phe-Leu-Gly (SEQ ID NO: 3), Val-Arg, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, Gln-Val, Asn-Ala, Gln-Phe, Gln-Ala, D-Ala-Pro, and D-Ala-tBu-Gly, wherein the first amino acid in each peptide is connected to L 2 group and the last amino acid in each peptide is connected to —NH-CR 1 R 2 —S—L 1 -D.
10. The compound of claim 9 , wherein A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly.
11. The compound of claim 1 , wherein D is represented by the following formula:
12. The compound of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
R 3 and R 4 are each independently H or Me;
r1 and t1 are each independently an integer from 1 to 6;
r2 and t2 are each independently an integer from 1 to 7;
t3 is an integer from 1 to 12; and
D 1 is represented by the following formula:
13. The compound of claim 12 , wherein A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly.
14. The compound of claim 12 , wherein R 3 and R 4 are both Me.
15. The compound of claim 12 , wherein R 3 and R 4 are both H.
16. The compound of claim 12 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly; and
D 1 is represented by the following formula:
17. The compound of claim 16 , wherein the compound is represented by the following formula:
wherein D 1 is represented by the following formula:
18. The compound of claim 17 , wherein the compound is represented by the following formula: